HIV infection in adults: A therapeutic update

American Journal of Managed Care

Volumn 5, Issue 8 SUPPL., 1999, Pages 1047-1060

  Thornton, Camille W ^a,b   Corbett, Cathy ^a,b   Brown, Richard ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; DRUG COST; DRUG INTERACTION; ECONOMICS; EDUCATION; FEMALE; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOPHYSIOLOGY; PREGNANCY; UNITED STATES;

ADULT; ANTI-HIV AGENTS; DRUG COSTS; DRUG INTERACTIONS; EDUCATION, PHARMACY, CONTINUING; FEMALE; HEALTH PERSONNEL; HIV INFECTIONS; HUMANS; MANAGED CARE PROGRAMS; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES; ZIDOVUDINE;

EID: 0033173777     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. World Health Organization. Weekly Epidemiological Record 1997;72:17-24.
2. Centers for Disease Control and Prévention. HIV/AIDS Surveillance Report. Mid-year edition. 1998;10{2):1-42.
3. Centers for Disease Control and Prevention. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR Surveillance Summary 1999;48(SS-2)1-22.
4. Carr A, Samara SK, Chisholm DJ, Cooper D. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;352:1881-1883.
5. Lo JC, Mulligan K, Tai VW, et al. Buffalo hump in men with HIV-1 infection. £anceM998;351:867-870.
6. Centers for Disease Control. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47(RR-5):1-46. Updated December 1, 1998.
7. Friedland GH. Adherence, compliance and HAART. AIDS Clinical Care 1997;9:51 -54.
8. Klaus BD, Grodesky MJ. Assessing and enhancing compliance with antiretroviral therapy. Nurse Practitioner 1997;22:211-219.
9. Andreoli TE, Bennett JC, Carpenter CC, et al, eds. HIV Infection and the Acquired Immunodeficiency Syndrome. Cecil Essentials of Medicine. 3rd ed. Philadelphia, PA: W. B. SaundersCo., 1993;702-719.
10. Weiss RA. HIV receptors and the pathogenesis of AIDS. Science 1996;272:1885-1886.
11. Moore JP. Co-receptors: Implications for HIV pathogenesis and therapy. Science 1997;2 76:51-52.
12. Niu MT, Jermano JA, Reichelderfer P, Schnittman SM. Summary of the National Institutes of Health workshop on primary human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1993;9:913-924.
13. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and sérologie markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. Transfusion 1995;35:91-97.
14. Haase AT/ Zupancic HE, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996;274:985-989.
15. O'BrienTR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 1996;276:105-110.
16. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-964.
17. Koup RA, S'afrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
18. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998;339:33-39.
19. SchackerT, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125:257-264.
20. Coombs R, Welles S, Hooper C, et al. Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-712.
21. + lymphocyte counts and the risk of progression to AIDS: Veterans Affairs Cooperative Study Group on AIDS. N Eng) Med 1996;334:426-431.
22. Brichacek B, Swindells S, Jannoff E, et al. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with vaccine. I Infect Dis 1996;174:1191-1199.
23. O'Brien W, Grovit-Ferbas K Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-1089.
24. Lerner BH, Gulick RM, Dubler NN. Rethinking nonadherence: Historical perspectives on triple-drug therapy for HIV disease. Ann /nf MecM998;129:573-578.
25. Carpenter C, Fischl M, Hammer S, et al. Antiretroviral therapy for the HIV infection in 1998: Updated recommendations of the International AIDS Society Panel-USA Panel. /4/U41998;280:78-86.
26. Garthwaite T, Kizer KW. Guidelines for AIDS Treatment in the VA System. VHSJ 1997;2:20-27.
27. Raboud J, Montaner J, Conway B, et al. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 1996;174:191 -194.
28. + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: A review. J Infect Dis 1992;165:352-363.
29. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;!26:946-954.
30. Enger C, Graham N. Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA 1996;275:1329-1334.
31. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl) Med 1996;335:1621-1629.
32. Schuurman R, Nijhuis M, Van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in person treated with lamivudine (3TC). ; Infect Dis 1995:171:1411 1419.
33. Keulen W, Back N, Van Wijk A, et al. Initial appearance of the >84lle variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1997;71:3346-3350.
34. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with or without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. /\/DS1998;12:F71-F77.
35. Montaner JS, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect D/s1997;175:801-806.
36. Montaner J, Reiss P, Cooper D, et al. A randomized double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial. JAMA 1998;279:930-937.
37. Perelson A, Neuman, A, Markowitz M, et al. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span and viral generation time. Science 1996;271:1582-1586.
38. Coffin J. Population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489.
39. Stephenson J. HIV drug resistance testing shows promise [news]. JAMA 1999;281:309-310.
40. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple ' concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998;128:906-911.
41. Tamalet C, Poizot Martin I, LaFeuillade A, et al. ANRS053 trial of zidovudine, lamivudine and ritonavir combination in patients with symptomatic primary HIV-1 infection. Presented at: 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington DC. Abstract 592.
42. Mehta S, Moore RD, Graham MH. Potential factors affecting adherence with HIV therapy. AIDS 1997;11:1665-1670.
43. Cespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurs AIDS Care 1997;8:4354.
44. Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with HIV: Prospective assessment with implications for enhancing compliance. AIDS Care !996;8:261-269.
45. Cardo DM, Culver DH, Ciesielski ÇA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997;337:1485-1490.
46. Centers for Disease Control. Public health service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR 1998;47(No. RR-7}:1-33.
47. Mast ST, Woolvvine JD, Gerberding JL. Efficacy of gloves in reducing blood volumes transferred during simulated needlestick injury. J Infect Dis 1993;168:1589-1592.
48. Ciesielski C, Metler R. Duration of time between expo-, sure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Am J Med 1997;102(suppl 5B):115-116.
49. Cerberding J, Henderson D. Management of occupational exposures to bloodborne pathogens: Hepatitis B virus, hepatitis C virus, and human immunodeficiency virus. Clin Infect Dis 1992;14:1179-1185.
50. Shih CC, Kaneshima H, Rabin L, et al. Postexposure prophylaxis with sidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis 1991 ;163:625-627.
51. National Institute of Health. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann /nf M?cM998;128:1057-1100.
52. Sperling R, Shapiro D, Coombs R, et al. Maternai viral load, zidovudine treatment, and the risk of transmision of human immunodeficiency virus from mother to infant. N Engl J Med 1996;335:1621 -1629.
53. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovim! 1997;! 6:54-62.
54. Nykamp D, Barnett CW, Lago M, et al. Cost of medication therapy in ambulatory HIV-infected patients. Ann Pharmacother 1 997;31:303-307.
55. Lé CT, Winter TD, Boyd KJ, et al. Experience with a managed care approach to HIV infection: Effectiveness of an interdisciplinary team. Am J Manag Care 1998;4:647-657.
56. Pinkerton S, Holtgrave D, Pinkerton H. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med 1997;157:1972-1980.
57. Mauskopf J, Paul J, Wichman .D et al. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening. JAMA 1996;276:132-138.
58. Gorsky R, Farnham P, Straus W, et al. Preventing perinatal transmission of HIV-costs and effectiveness of a recommended intervention. Public Health Rep 1996;111:335-341.